Dr. Joan Montaner has participated in this video explaining the results of our project AFRICAT funded by La Marató de TV3 in its 2014 edition.
New multicenter project:BIOTRABIS (Biomarkers of traumatic Brain injury-Spain)
This is a longitudinal, prospective, non-observational, without drugs, multicenter study, which include patients with mild TBI of less than twenty-four hours of evolution, recruited in the emergency services of the participating centers.
more information: http://www.biotrabis.com
New H2020 project : AFFECT-EU
Digital, risked-based screening for Atrial Fibrillation in the European Community
Atrial fibrillation (AF) is an increasingly common arrhythmia in the aging European population. Its prevalence will more than double by the year 2050 affecting 5% of EU women and men aged ≥65 years. AF carries a high risk of stroke, heart failure, and dementia, which result in a significant loss of quality-adjusted life years and high mortality. The EU guiding principles for active aging (no. 17468/12) recommend disease prevention to maximise healthy life, and early detection of AF is recommended by the European Society of Cardiology (ESC). Nonetheless, to date, a risked-based screening strategy is lacking.
AFFECT-EU’s major goal is the development of a risk-based, accurate, and ready for implementation AF screening algorithm, using digital devices, for early AF detection in the community.
FIPSE (Fundación para la Innovación y la Prespectiva en Salud en España) has recently funded our project entitled: COMBO-4-Stroke.
The aim of these grants is financing feasibility studies that make it possible to put new healthcare technologies, based technically and financially viable, at the disposal of health services, and make it possible for them to be incorporated in the Spanish healthcare system.
In this project we want to keep on working with two promising treatments, based on
the synergic effects of two-by-two combinations of drugs previously approved by the FDA for other medical indications. We have found promising neuroprotective effects in pre-clinical experimentation: both drug combinations – but not individual drugs – are highly effective in reducing the brain ischemic lesion in animals following ischemic stroke. Our multidisciplinary team of clinicians and biologists strongly believes that the use of these combinations of drugs (COMBO-4-STROKE) in daily clinics might reduce social and economic repercussion of this devastating disease.
On this basis, FIPSE program is a good opportunity to create and implement a specific valorization and commercialization plan to ultimately these treatments to the market, since the economical revenues of this strategy, if useful, would be massive.
Tereza Mráčková, is a junior researcher who works at BioVendor – Laboratorní Medicína a.s. BioVendor LM is an internationally active biotechnology company with its own research, development and manufacturing and international sales and marketing network. It has specialized in the development of original immunoassay kits for the detection of novel hormone-like proteins and protein biomarkers as well as related antibodies and recombinant proteins. Recently they are also focusing on novel topics known to be of great interest among the scientific and diagnostic community – microRNA biomarkers, liquid biopsy, exosome isolation, and immunodiagnostic multiplexing and automation.
Tereza is also a PhD student in the Stroke Program at the International Clinical Research Center (St. Anne’s University Hospital BRNO).
She is spending some days at our laboratory to test some miRNAs that could be connected to stroke diagnosis and prognosis.
On January 22nd, the neurovascular research laboratory held its first Retreat.
It has been an opportunity, especially for people who have recently joined the group, to learn a little about our history and the main lines of research.
We have had the collaboration of a gamification expert who has organised games and quizzes focused on knowing each other. We have also put in common the objectives to achieve in 2018 and what we believe we can improve.
Dr. Anna Rosell will be the coordinator of a new H2020 project (EURONANOMED call).
Title: New MAGnetic Biomaterials for Brain Repair and Imaging after Stroke (MAGBBRIS)
According to the World Health Organization, 15 million persons suffer a stroke worldwide each year, and neuro-repair treatments could offer the opportunity to treat stroke patients by extending the therapeutic time window.
By engineering novel magnetic nano-biomaterials we will achieve tissue repair in the context of an ischemic event. We will take advantage of nanotechnology to deliver therapeutic growth factors, secreted by progenitor cells, into the injured brain. MAGBBRIS will demonstrate that growth factors, secreted by endothelial progenitor cells, with proved potential to induce tissue repair, can be encapsulated in magnetic biomaterials and be successfully and safely transplanted into mouse brains with the guidance of magnetic fields, to induce tissue repair.
MAGBBRIS consortium is made up by highly multidisciplinary materials-science, biomedical and clinical research with industrial partnership. The project will provide a new medicinal product ready to be tested in a preclinical multicentric study.
Dr. Anna Rosell, Vall d’Hebron Research Institute. Barcelona, Spain.
Dr. Anna Roig, Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC). Institut de Ciència de Materials de Barcelona (ICMAB). Bellaterra, Spain.
Dr. Fabien Gosselet, University of Artois, Faculty Jean Perrin. Lens, France.
Dr. Maria Picchio, Ospedale San Raffaele IRCCS. Milano, Italy.
Dr. Filip Jelen, Pure Biologics Ltd. Wrocław, Poland.
Dr. Peter Kopcansky, Institute of experimental physics, Slovak Academy of Sciences, SAS. Kosice, Slovakia.
New H2020 project : PRESTIGE AF
PREvention of STroke in Intracerebral hemorrhaGE survivors with Atrial Fibrillation
Intracerebral hemorrhage (ICH) is a severe stroke subtype causing higher mortality and more disability than other strokes. 20% of ICH survivors have atrial fibrillation (AF), a major cause of ischemic stroke (IS). While IS in AF patients is generally prevented by oral anticoagulants (OAC), their use in ICH survivors is uncertain due to increased bleeding risk. No evidence from randomized controlled trials (RCT) is available addressing this dilemma. Personalized risk prediction is desirable to balance benefits of OAC against bleeding risk for individualized prevention.
Objectives: (1) To perform the first sufficiently powered RCT in ICH survivors with AF testing if direct OAC are superior for IS prevention and non-inferior regarding ICH recurrence versus antiplatelet or no antithrombotic therapy (2) To personalize antithrombotic prevention by multidimensional risk modeling (3) To estimate population impact of trial outputs on health economic consequences and generalizability to European population (4) To explore patient-centered aspects including
adherence, attitudes towards antithrombotic therapy and gender imbalances in trial enrollment.
PRESTIGE-AF addresses the unmet need of best antithrombotic stroke prevention in ICH patients with AF. Recurrent stroke reduces individual life expectancy, quality of life and has high public health impact. Work packages integrating biological data will generate new tools to tailor prevention. Modeling of economic and societal consequences and replication in real-life settings will estimate population impact.
OUR RESEARCH LINES
- octubre 2020
- junio 2020
- mayo 2020
- enero 2020
- abril 2019
- noviembre 2018
- septiembre 2018
- enero 2018
- noviembre 2017
- septiembre 2017
- marzo 2017
- noviembre 2016
- octubre 2016
- mayo 2016
- febrero 2016
- diciembre 2015
- noviembre 2015
- junio 2015
- mayo 2015
- abril 2015
- marzo 2015
- febrero 2015
- enero 2015
- noviembre 2014
- octubre 2014
- septiembre 2014
- agosto 2014
- julio 2014
- junio 2014
- mayo 2014
- abril 2014
- marzo 2014
- febrero 2014
- enero 2014
- diciembre 2013
- octubre 2013
- septiembre 2013